Mechanism Of Action:
Venetoclax, as the first and only BCL-2 inhibitor, plays a crucial role in restoring the apoptotic process in newly diagnosed acute myeloid leukemia (AML). The suppression of the apoptotic pathway is a critical mechanism for the survival and proliferation of hematologic cancer cells. These findings are supported by preclinical studies.
Indication:
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are similar diseases that primarily affect lymphocytes, a type of white blood cell. The treatment approach for CLL and SLL can be similar, and there are several options available depending on the stage and characteristics of the disease.
One notable treatment option that has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of CLL/SLL is ibrutinib (Imbruvica). Ibrutinib is a targeted therapy that inhibits a protein called Bruton’s tyrosine kinase (BTK), which is involved in the survival and proliferation of CLL and SLL cells. It is generally recommended among the first-line treatment options for symptomatic CLL.
Acute Myeloid Leukemia (AML)
Venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine, is employed as a treatment for newly diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older or have comorbidities that make them unsuitable for intensive induction chemotherapy. This therapeutic approach is specifically recommended to address the needs of these patient populations
